# Hypofractionated vs. Conventionally Fractionated Concurrent CRT for Unresectable Stage III NSCLC

> **NCT03331575** · PHASE3 · UNKNOWN · sponsor: **Shanghai Chest Hospital** · enrollment: 480 (estimated)

## Conditions studied

- Unresectable Stage III Non-small-cell Lung Cancer

## Interventions

- **RADIATION:** Arm1 (Hypofractionated radiotherapy)

## Key facts

- **NCT ID:** NCT03331575
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-11
- **Primary completion:** 2020-11
- **Final completion:** 2020-11
- **Target enrollment:** 480 (ESTIMATED)
- **Last updated:** 2017-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03331575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03331575, "Hypofractionated vs. Conventionally Fractionated Concurrent CRT for Unresectable Stage III NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03331575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*